Skip to content
Review Open access

Effect of immunomodulatory therapies on mortality in adults hospitalised with COVID-19 and non-COVID-19 community-acquired pneumonia: A systematic review and meta-analysis.

Nov 2026 · Clinical Microbiology and Infection · 0 citations · 31 references
Medicine

Abstract

Background

Community-acquired pneumonia (CAP) is the leading infectious cause of morbidity and mortality globally. Severe disease is driven by a dysregulated host inflammatory response, leading to tissue damage. Despite numerous immunomodulatory strategies studied in CAP, their effectiveness remains unclear.

Objective

To assess the effectiveness of immunomodulatory therapies on 30-day and 90-day mortality in adults hospitalised with CAP. METHODS/DATA SOURCES Medline (via Ovid), Embase (via Ovid), Web of Science (Core Collection), Scopus, and Global Health (via Ebscohost) were searched from inception to 9 December 2025. STUDY ELIGIBILITY CRITERIA All studies investigating the use of immunomodulatory therapies in adult patients hospitalised with CAP.

Participants

Adult patients admitted to hospital with CAP.

Interventions

Any immunomodulatory therapy initiated for the management of CAP. ASSESSMENT OF RISK OF BIAS RoB2 was used for RCTs and ROBINS-I for non-randomised studies of interventions.

Methods

OF DATA SYNTHESIS Treatments were grouped into pre-specified categories, then analysed in a series of pairwise random-effects meta-analyses. Pre-specified subgroup analyses were undertaken regarding severity, aetiology and individual treatments within selected categories. COVID-19 and non-COVID-19 CAP analyses were performed separately.

Results

196 studies, including 89,117 patients, were included. Nine treatment categories included five or more randomised controlled trials (RCTs) reporting 30-day mortality. Among these, corticosteroids, cytokine inhibitors (predominantly IL-6), and JAK inhibitors were associated with reduced 30-day mortality in COVID-19, with odds ratios of 0.87 (95% CI 0.765-0.999), 0.84 (95% CI 0.76-0.93), and 0.66 (95% CI 0.47-0.93), respectively. The only therapies evaluated in five or more RCTs reporting 90-day mortality were cytokine inhibitors in COVID-19 CAP (OR 0.68, 95% CI 0.45-1.03). No therapies were consistently associated with reduced mortality in non-COVID-19 CAP.

Conclusions

Cytokine inhibitors reduce 30-day mortality while corticosteroids and JAK inhibitors probably reduce 30-day mortality in adults hospitalised with COVID-19 CAP. Further research is needed to identify effective immunomodulatory strategies for non-COVID-19 CAP. SYSTEMATIC REVIEW REGISTRATION PROSPERO ID - CRD42024565301.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.